Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

11,350articles mentioning institutions

22,378institution mentions

9,137distinct institutions extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted institutions

Showing 421–480 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.

Swedish Medical Products Agency4 University of Toronto4 eye banks4 Aarhus University Hospital4 Alder Hey Children’s Hospital4 Amsterdam University Medical Centre4 Anesth Analg4 BCS4 British Cardiovascular Intervention Society4 Griffith University4 IHI4 IQVIA4 Infectious Diseases Unit4 NUH4 OSF4 Peking Union Medical College4 Piraeus Medical4 St. James’s Hospital4 Sun Yat-sen University4 US4 University of California San Diego4 University of California San Francisco4 University of Sydney4 University of Utah4 ANSM4 Aberdeen Royal Infirmary4 Academic Search Complete4 American Academy of Pediatrics4 American Thoracic Society4 Anhui Medical University4 Asan Medical Center4 Australia4 BMC Nurs 20254 BMJ Oncology4 Beaumont Hospital4 Belfast Heart Attack Centre4 Beth Israel Deaconess Medical Center4 Bristol Royal Infirmary4 Cambridge University Hospitals4 Centre4 Charles River Laboratories4 China Academy of Chinese Medical Sciences4 Chinese BioMedical Literature Database4 Clinical Trial Registry of India4 Clinical Trials Ontario4 Cochrane Database4 Dana-Farber/Harvard Cancer Center4 Doctors4 EconLit4 Eli Lilly4 Eur Heart J4 European Society for Medical Oncology4 European Society of Gastrointestinal Endoscopy4 First Affiliated Hospital of Sun Yat-Sen University4 Fox Chase Cancer Center4 Frontline Gastroenterology4 GE HealthCare4 GMC4 German Stroke Registry4 Ghent University4

View all 9,137 institutions on one page

Articles mentioning institutions

11,350 articles · page 313 of 946

588 Selective inhibition of Diacylglycerol kinase zeta exhibits increased T cell activation and anti-tumor immunity, demonstrating pharmacodynamic proof of mechanism in the FIH trial of BAY2965501

jitc · abstract · 2025-11-04 · 2 matching annotations

91.3%

NCT05614102 BAY2965501 pembrolizumab BAY2965501-induced solid tumors IRBs

…ing investigated in a FIH dose-escalation and expansion study ( NCT05614102) to evaluate safety, pharmacokinetics and pharmacodynamics, in …

58 The 31-gene expression profile identifies node-negative patients with cutaneous melanoma who have a high risk of melanoma-specific and all-cause mortality

jitc · abstract · 2025-11-04 · 2 matching annotations

83.6%

J Invest Dermatol National Cancer Institute CM ACM cutaneous melanoma

…mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol. 2015 Apr;135(4):1190–3.Ethics Approval IRB approval not applic…

595 Preliminary results of safety and antitumor activity from a first-in-human phase 1 study of AWT020, a bifunctional anti-PD-1/IL-2 fusion protein, in patients with advanced tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

87.7%

Alfred Health Bellberry Limited AWT020 thymic carcinoma cholangiocarcinoma mesothelioma neuroendocrine renal carcinoma neuroendocrine non-small cell lung cancer

…alia Ethics Committees: Bellberry Limited (2023-06-698-A-6) and Alfred Health (HREC/100137/Alfred-2023). All patients provided informed conse…

5 Immunomodulation of tumor microenvironment in triple negative breast cancer by reversing hypoxia with NanO2, a novel oxygen delivery agent

jitc · abstract · 2025-11-04 · 2 matching annotations

82.9%

BALB/c mice GWUC NanO 2 Glioblastoma Multiforme NanO2 Paclitaxel TNBC Triple-negative breast cancer DOD Grant

…herapy (IT), chemotherapy (CTX, paclitaxel) or both IT and CTX. BALB/c mice were treated for three weeks starting on day 3 post-implantatio…

604 Phase 2 study of neoadjuvant nivolumab + relatlimab versus nivolumab in patients with resectable high-risk basal cell carcinoma

jitc · abstract · 2025-11-04 · 2 matching annotations

95.5%

University of California Cancer Centers UC San Diego basal cell carcinoma cutaneous squamous-cell carcinoma cutaneous squamous cell carcinoma ECOG Performance Status RELA nivolumab NIVO relatlimab

…e high-risk BCC.Methods This multicenter study open at multiple University of California Cancer Centers will enroll up to 30 patients with resectable high-risk BCC. Hi…

618 A multicomponent intratumoral chemo-immunotherapeutic approach is effective in a canine metastatic thyroid cancer patient

jitc · abstract · 2025-11-04 · 2 matching annotations

91.3%

Hospital Oncológico Veterinario La Rioja National Autonomous University of Mexico liposomal doxorubicin oxaliplatin combretastatin A4 Phosphate hTC Canine thyroid carcinomas (CTCs)CA4P acPD-1 CFTC

…erous and supportive of the present study, the personnel of the Hospital Oncológico Veterinario La Rioja for their help, and the Canine Cancer Alliance (https://www.ccr…

61 Fully automated multiomics assay for co-detection of protein-protein interactions, RNA and protein markers on the same tissue section

jitc · abstract · 2025-11-04 · 2 matching annotations

81.7%

COMETTM platform cancer

…ethods We developed a fully automated multiplex workflow on the COMETTM platform capable of staining and imaging protein-protein interactions, m…

620 ROS1, RET, and BRAF V600E NSCLC exhibit immune-favorable features and benefit from chemo-immunotherapy

jitc · abstract · 2025-11-04 · 2 matching annotations

94.1%

Chinese Academy of Medical Sciences Cancer Hospital Shanxi Cancer Hospital bevacizumab Non-small cell lung cancers platinum-based chemotherapy NSCLCs

…ranged, 53 RET-rearranged, 48 BRAF V600E-mutant) treated at the Chinese Academy of Medical Sciences Cancer Hospital and Shanxi Cancer Hospital from 2018–2022 (median follow-up 26.…

627 Soluble immune modulatory cytokines and immune checkpoint molecules as predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

jitc · abstract · 2025-11-04 · 2 matching annotations

90.9%

National Center for Cancer Care and Research Hamad Medical Corporation NSCLC non-small cell lung cancer

…herapy in NSCLC patients.Methods The study was conducted at the National Center for Cancer Care and Research, Hamad Medical Corporation, Qatar from September 2021-June 2023…

630 Anti-CD40 and epigenetic modifier inhibitors to augment treatment of high-risk neuroblastoma

jitc · abstract · 2025-11-04 · 2 matching annotations

96.2%

National Cancer Institute UW Flow Cytometry Core Facility Neuroblastoma guadecitabine aCD40 aGD2 entinostat

… Childhood Cancer; and by public health service grants from the National Cancer Institute: Alex’s Lemonade Stand Foundation, the Hartwell Foundation, Mid…

635 The impact of bispecific antibody CD22xCD28 on anti-tumor efficacy of odronextamab and T cell activation and function in B cell tumor models

jitc · abstract · 2025-11-04 · 2 matching annotations

79.7%

National Institutes of Health NCT05685173 Odronextamab non-Hodgkin lymphoma REGN5837 odronextamab-mediated DLBCL follicular lymphoma

…ith the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Regeneron Pharmaceuticals I…

637 Two targets – two signals: dual bispecific antibody therapy targeting CD276 and FAP by engaging CD3 and CD28 for solid tumor immunotherapy

jitc · abstract · 2025-11-04 · 2 matching annotations

90.1%

University Hospital Tuebingen Eberhard Karls Universitaet Tuebingen solid tumors BiCo-3 NCT05999396 CD276xCD3 bsAb CC-3 bsAbs

…al Faculty of the Eberhard Karls Universitaet Tuebingen) at the University Hospital Tuebingen and was conducted in accordance with the Declaration of Helsink…